The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted by 16 to one that PT027 should be approved for use in adults ... “transform the current rescue treatment approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback